1. Home
  2. RYTM vs BCO Comparison

RYTM vs BCO Comparison

Compare RYTM & BCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • BCO
  • Stock Information
  • Founded
  • RYTM 2008
  • BCO 1859
  • Country
  • RYTM United States
  • BCO United States
  • Employees
  • RYTM N/A
  • BCO N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • BCO Oil Refining/Marketing
  • Sector
  • RYTM Health Care
  • BCO Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • BCO Nasdaq
  • Market Cap
  • RYTM 4.3B
  • BCO 3.7B
  • IPO Year
  • RYTM 2017
  • BCO N/A
  • Fundamental
  • Price
  • RYTM $65.25
  • BCO $92.71
  • Analyst Decision
  • RYTM Strong Buy
  • BCO Strong Buy
  • Analyst Count
  • RYTM 12
  • BCO 1
  • Target Price
  • RYTM $77.50
  • BCO $138.00
  • AVG Volume (30 Days)
  • RYTM 560.2K
  • BCO 357.9K
  • Earning Date
  • RYTM 08-05-2025
  • BCO 08-06-2025
  • Dividend Yield
  • RYTM N/A
  • BCO 1.14%
  • EPS Growth
  • RYTM N/A
  • BCO 41.25
  • EPS
  • RYTM N/A
  • BCO 3.72
  • Revenue
  • RYTM $136,863,000.00
  • BCO $5,022,500,000.00
  • Revenue This Year
  • RYTM $37.56
  • BCO $3.91
  • Revenue Next Year
  • RYTM $74.99
  • BCO $4.45
  • P/E Ratio
  • RYTM N/A
  • BCO $24.14
  • Revenue Growth
  • RYTM 48.88
  • BCO 1.97
  • 52 Week Low
  • RYTM $40.46
  • BCO $80.10
  • 52 Week High
  • RYTM $69.89
  • BCO $115.91
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • BCO 59.76
  • Support Level
  • RYTM $60.80
  • BCO $88.22
  • Resistance Level
  • RYTM $64.00
  • BCO $90.24
  • Average True Range (ATR)
  • RYTM 1.96
  • BCO 1.71
  • MACD
  • RYTM -0.13
  • BCO 0.56
  • Stochastic Oscillator
  • RYTM 44.48
  • BCO 81.64

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BCO Brinks Company (The)

The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.

Share on Social Networks: